BREAKING: FDA Executive Officer Reveals Future COVID-19 Policy on Hidden Camera (WATCH)

Christopher Cole, FDA Executive Officer of Countermeasures Initiative, revealed the Biden administration’s future COVID-19 policy on hidden footage obtained by Project Veritas.

The 20-year veteran of the agency claims to be directly involved in the approval process of the experimental COVID-19 injections.

Cole states Biden wants to inoculate as many individuals as possible and wants everyone to take an annual COVID-19 injection (including kids).

The agency’s executive officer reiterates the reason the policy hasn’t been announced yet is to not “rile everyone up.”

Cole continues by discussing the gargantuan amounts of money food companies, drug companies, and vaccine companies pay the FDA to keep the reviewers that approve their products.

According to Cole, the FDA receives hundreds of millions of dollars per year.

As we’ve long expected, an annual COVID-19 “vaccine” would earn the pharmaceutical companies a substantial amount of annual profits.

When asked how he knows if it’s getting approved (COVID-19 jab for toddlers), Cole affirms they’re (FDA) not going to not approve it.

The Project Veritas journalist presses Cole further on the topic of toddler COVID-19 jabs, and he states, “the three will bolster your system.”

He predicts that schools will eventually mandate the COVID-19 injections for attendance.

“So, the toddlers too, then will have to get it annually?” the PV journalist asks. Cole responds, “probably.”

Cole adds that he doesn’t agree with the FDA’s process, saying “all the tests aren’t there.”

While Cole admits there isn’t as much assurity for parents with the COVID-19 jabs, he still thinks it’s important to inoculate them (toddlers).

He reiterates the shots are under Emergency Use Authorization (EUA) for all age groups, confirming they’re experimental shots.

When pressed if COVID-19 is an emergency for toddlers, Cole explains, “the efficacy data doesn’t need to be as high.”

Even though cases are low for six-month to four-year-olds, Cole notes that the COVID-19 designation places the injections underneath the EUA process.

And that means the efficacy data doesn’t need to be as high to approve an experimental shot for a group that doesn’t need it.

Watch the footage of Christopher Cole below:

https://twitter.com/ExposeFDA/status/1493751083113582592

Watch the full clip on Rumble:

Project Veritas writes:

Cole is an Executive Officer heading up the agency’s Countermeasures Initiatives, which plays a critical role in ensuring that drugs, vaccines, and other measures to counter infectious diseases and viruses are safe. He made the revelations on a hidden camera to an undercover Project Veritas reporter.

SIGN THE PETITION: We Need National Voter ID!

Cole indicates that annual COVID-19 shots isn’t probable — but certain. When pushed on how he knows an annual shot will become policy, Cole states, “Just from everything I’ve heard, they [FDA] are not going to not approve it.”

The footage, which is part one of a two-part series on the FDA, also contains soundbites from Cole about the financial incentives pharmaceutical companies like Pfizer have to get the vaccine approved for annual usage.

“It’ll be recurring fountain of revenue,” Cole said in the hidden camera footage. “It might not be that much initially, but it’ll recurring — if they can — if they can get every person required at an annual vaccine, that is a recurring return of money going into their company.”

Perhaps the most explosive part of the footage is the moment where Cole brazenly talks about the impact that an Emergency Use Authorization has on overcoming the regulatory concerns of mandating vaccines on children.

“They’re all approved under an emergency just because it’s not as impactful as some of the other approvals,” Cole said when asked if he thought there was “really an emergency for kids.”

Cole, who claims his role with the FDA is to ensure the agency uses a framework of safety, security, and effectiveness as a part of its preparedness and response protocol, specifically cited concerns over “long term effects, especially with someone younger.”